Source: PTSM: Pharmaceutical Technology Sourcing and Management
Issue 9,Volume 3
People on the move.
People on the move.
Fremont, CA (Aug. 21)—PDL BioPharma'schief executive Mark McDade will resign by the end of 2007. An internal investigation found no credible evidence of improper personal conduct or breach of fiduciary duty.
Stockholm, Sweden (Aug. 17)— Orexoappointed three senior executives: Mats Eriksson, PhD, to vice-president of research and clinical development and medical director; Christina Ståhl, MSc. Pharm, to vice-president of regulatory affairs; and Anne Marie Ciupitu, MSc, PhD, to director of quality assurance and quality control
Woburn, MA (Aug. 15)—BioVex, a biotechnology company developing clinical-stage treatments, appointed Dr. Thaddeus Pullano as vice-president of quality assurance.
Palo Alto, CA (Aug. 14)—Affymax named Robert Venteicher as the company's vice-president of technical operations. In this position, Venteicher will oversee manufacturing and process development, quality, and facility operations for Affymax.
Shanghai, China (Aug. 13)—WuXi PharmaTech, a provider of pharmaceutical research and development outsourcing services, appointed Edward Hu executive vice-president of operations. Hu will report directly to Ge Li, chairman and chief executive officer of the company.
Westbrook, ME (Aug. 13)— Artel, a provider of liquid-handling quality assurance, appointed Bjoern Carle, PhD, laboratory applications scientist.
Markham, ON, Canada (Aug. 13)—Joel Z. Melnick, MD, joined Cytochroma as vice-president of clinical and regulatory affairs. Melnick will be responsible for managing the clinical development of Cytochroma's new Vitamin D therapies and for obtaining marketing approvals from the US Food and Drug Administration and Canada's Therapeutic Products Directorate.
New York (Aug. 10)—The pharmaceutical company ImClone Systemsappointed John H. Johnson as its chief executive officer, effective August 27, 2007.
Vancouver, BC, Canada (Aug. 10)—ProtoKinetix appointed Ross L. Senior its president and CEO.
Toronto, ON, Canada (Aug. 9)—PharmEng International, a consulting and contract manufacturing company, appointed David G. Leonard the Keata Pharma president for the Sydney, Nova Scotia, Canada, and Perth, Ontario, Canada, manufacturing sites. Keata Pharma is a wholly owned subsidiary of PharmEng with manufacturing facilities in Perth and new facilities in Sydney scheduled to open in the fourth quarter of this year.
Bridgewater, NJ (Aug. 9)—Sapphire Therapeutics,a private biopharmaceutical company, announced a promotion and a new addition to the firm. Eleanor de Groot was promoted to vice-president of technical operations, with increased responsibilities for all drug development and manufacturing activities at the company. Brenda Marczi will join Sapphire as vice-president of regulatory affairs.
Corona, CA (Aug. 2)—Watson Pharmaceuticals announced that Allen Chao, Ph.D., 61, its chairman, president and chief executive officer, will retire as president and chief executive officer, effective September 4, 2007. Chao will be succeeded by Paul M. Bisaro, 46, currently president and chief operating officer of Barr Pharmaceuticals(Woodcliff Lake, NJ), who has been named president and chief executive officer of Watson, effective September 4, 2007. Bruce L. Downey, Barr's chairman and chief executive officer, will assume these responsibilities on an interim basis.
Abbott Park, IL (Aug. 3)—Richard A. Gonzalez, president and chief operating officer, and a member of Abbott's board of directors, plans to retire after a 30-year career with the company. Gonzalez will remain with Abbott until Sept. 30, 2007.
Thousand Oaks, CA (Aug. 2)—Amgen announced that Dennis Fenton, executive vice-president of operations, has elected to retire at the end of 2007 after 25 years with the company.
San Diego, CA (Aug. 2)—BioDuro, a life-sciences outsourcing company for the pharmaceutical and biotechnology industry with headquarters in San Diego, CA, and laboratory facilities in Beijing, China, appointed Steven M. Hutchins to the position of vice-president, business development and collaboration management.
Paris (Aug. 1)—David J. Williams relinquished his titles of president and chief executive officer of Sanofi Pasteur,the vaccines division of the Sanofi-Aventis Group . He will continue to serve as chairman of the board of Sanofi Pasteur until January 16, 2008, which will also mark his 30th anniversary with the company. His successor will be Wayne Pisano, formerly senior vice-president, global commercial operations and corporate strategy.